Pharmacotherapy for Obesity — Promise and Uncertainty
Author:
- Susan Z. YanovskiSYSusan Z. Yanovski
- 17 November 2005
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (20) , 2187-2189
Abstract
In 2005, a majority of adult Americans are overweight or obese,1 putting millions of them at increased risk for serious medical conditions, including cardiovascular disease, type 2 diabetes mellitus, and certain forms of cancer. In obesity, a weight loss of 5 to 10 percent can significantly improve risk factors for obesity-related diseases2 and delay or prevent type 2 diabetes in persons at high risk.3 Behavioral treatments can result in a weight loss sufficient to improve health for many patients, but often the weight is regained over time.4 Although for many people a reduction in weight is difficult to achieve, maintaining . . .Keywords
This publication has 12 references indexed in Scilit:
- Randomized Trial of Lifestyle Modification and Pharmacotherapy for ObesityNew England Journal of Medicine, 2005
- Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with DyslipidemiaNew England Journal of Medicine, 2005
- Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite SuppressantsAnnals of Internal Medicine, 2005
- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe studyThe Lancet, 2005
- Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawalPreventive Medicine, 2004
- Prevalence and Trends in Obesity Among US Adults, 1999-2000JAMA, 2002
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- BEHAVIORAL TREATMENT OF OBESITYMedical Clinics of North America, 2000
- Executive SummaryObesity Research, 1998
- IntroductionClinical Pharmacology & Therapeutics, 1992